The divalent cation chelators, ethyleneglycoltetraacetic acid (EGTA) and its magnesium salt, MgEGTA, were compared in studies of alternative complement pathway function. EGTA (0.01 M) inhibited both the rate and the amount of complement activation by zymosan whether compared to nonchelated serum or to serum chelated with MgEGTA (0.01 M). The rate of alternative pathway activation by zymosan was slightly slower in MgEGTA-chelated serum than in nonchelated serum, but the overall amount of complement consumed by a given amount of zymosan was not decreased. MgEGTA chelation spontaneously activated the alternative pathway, as reflected by lysis of erythrocytes from a patient with paroxysmal nocturnal hemoglobinuria. No evidence could be found that MgEGTA either spontaneously activated C2 or facilitated zymosan activation of C2. Suggested guidelines for the use of these chelators are advanced.
Differential divalent cation chelation of serum using ethyleneglycoltetraacetic acid (EGTA) has provided a useful method for study of the alternative complement (C) pathway (5) . The method depends upon the fact that, whereas the classical C pathway requires both calcium and magnesium, the alternative pathway requires only magnesium (13) . EGTA, by chelating calcium considerably more avidly than magnesium, blocks the classical pathway selectively. The magnesium level in EGTAchelated serum is, however, lower than normal-enough lower that alternative pathway function is partially impaired (1, 3, 6) . The magnesium salt of EGTA (MgEGTA) also binds calcium avidly but supplies normal (actually supranormal) levels of magnesium in chelated serum (2) and has been suggested as the preferable form of the chelator for alternative pathway study (1, 6) . Enthusiasm for the use of MgEGTA has, however, been dampened by evidence that excessive magnesium per se, either as MgCl2 (9, 10) or as MgEGTA (3) , activates the alternative pathway and perhaps even the classical pathway.
This paper explores the kinetics of alternative pathway activation in the presence of the chelators EGTA and MgEGTA, reconfirms the findings of alternative pathway activation by MgEGTA, but fails to confirm evidence that MgEGTA, either alone or in concert with zymosan, activates the classical pathway at the level of the second component (C2).
MATERIALS AND METHODS
Serum. Human blood from healthy adult male volunteers was collected by venipuncture; guinea pig blood from healthy outbred animals was obtained by cardiac puncture. After clotting for 2 h at room temperature, blood was centrifuged (2,500 x g) and serum was stored at -70°C in 1-ml aliquots until just prior to use. Once thawed, unused serum was discarded.
Chelators and divalent cation salts. EGTA (Sigma Chemical Co., St. Louis, Mo.) and EDTA (Matheson Coleman and Bell Manufacturing Chemists, Norwood, Ohio) were prepared in 0.1 M stock solutions as previously described (5) . MgEGTA was prepared in 0.1 M stock solution as described by Bryan (1). Serum was chelated by addition of 0.1 ml of stock solution to each 1 ml of serum for a final chelator concentration of approximately 0.01 M (5).
Zymosan. Stock solutions of zymosan (Z, Nutritional Biochemicals Corp., Cleveland, Ohio) were prepared as previously described (5 (12) . Hemolytic titrations of the lateacting components C3 to C9 (i.e., C3-9) were performed using the following modification of methods of Rapp and Borsos (12) and Kabat and Mayer (8): 1-ml aliquots of sheep erythrocytes sensitized with 19S antibody, Cl, C4, and C2 by the method of Rapp and Borsos (12) were added to 6.0 ml of serum diluted serially in EDTA buffer. After 60 min of incubation at 37°C, tubes were centrifuged at 1,200 x g for 10 min, and optical density (412 nm) ofthe supernatant fluid was determined. Percentage of lysis was plotted against relative concentration of serum to determine the 50% end point.
Statistical methods. Values were compared using Student's paired t test.
RESULTS
Effect of incubation time. Z was suspended at a concentration of 1 mg/ml in serum containing MgEGTA or EGTA (0.01 M) or an equivalent volume of saline. Aliquots of serum were withdrawn at 0, 15, 30, 45, and 60 min and diluted immediately in ice-cold EDTA buffer. When all samples had been obtained, C3-9 titrations were performed. Results were expressed as percentage of time 0 serum C3-9 titer under the particular chelation conditions. Figure 1 shows the results from four experiments in human serum. In nonchelated serum, essentially all C3-9 had been consumed in the reaction with Z by 15 min. C activation was slower in MgEGTA-chelated serum (03-9 at 15 min significantly higher than in nonchelated serum, P < 0.025) but was complete by 30 min. In EGTA-chelated serum, C3-9 values at 15 and 30 min were significantly higher than values in either MgEGTA-chelated (15 min, P < 0.05; 30 min, P < 0.01) or nonchelated (15 min, P < 0.001; 30 min, P < 0.025) serum. Although complete consumption did not seem to occur even at 60 min in EGTA-chelated serum, differences at 45 and 60 min did not reach statistical significance. Similar studies in guinea pig serum are not shown but gave similar results.
Effect of Z concentration. To demonstrate differences at 60 min, varying concentrations of Z were incubated with chelated or nonchelated serum. Z was suspended in human serum at final concentrations ranging from 0.2 to 1.2 mg/ ml. After 60 min of incubation, serum was diluted in ice-cold EDTA buffer and residual C3-9 was measured (Fig. 2) . Since there were no differences among the various baseline C3-9 titers in the experiments seen in Fig. 1 (i.e., chelation did not affect the baseline C3-9 titer), all values in this experiment were expressed as percentage of the C3-9 titer of nonchelated nonchallenged serum. Z consumed more C in Mg-EGTA-chelated serum than in nonchelated serum at concentrations of 0.2 (P < 0.02) and 0.4 mg/ml (P < 0.025). Less C was consumed in EGTA-chelated serum than in nonchelated serum at concentrations of 0.4 (P < 0.05) and 0.8 mg/ml (P < 0.01) and less than in MgEGTAchelated serum at concentrations of 0.2 (P < 0.025), 0.4 (P < 0.02), and 0.8 mg/ml (P < 0.02). (13) . This differing requirement for calcium can be exploited experimentally using EGTA, a substance which chelates calcium avidly but magnesium weakly (2) . Essentially, C consumption uninhibited by EGTA (i.e., calcium independent) is assumed to proceed through the alternative pathway. The original application of this technique to studies of the alternative pathway utilized undiluted human serum, Z in a concentration of 2 mg/ml of serum, 60 min of incubation at 370C, and measurement of whole hemolytic C (CH50) consumption as a reflection of C activation (5) . Subsequent studies suggested that guinea pig C was more unstable in EGTA-chelated serum than was human C (4).
Platts-Mills and Ishizaka demonstrated that the effect of EGTA on C was attributable to dissolution of Cl after chelation of calcium, the ligand which holds the Cl trimolecular complex together (11) . In their studies, they used the magnesium salt of EGTA (MgEGTA). EGTA (0.01 M), although only a weak chelator of magnesium (log Ka = 5.4), will reduce the magnesium concentration of human serum from the on November 2, 2017 by guest http://iai.asm.org/ Downloaded from normal level of 1 x 10-3 M to approximately 1.6 x 10-6 M; it will reduce the calcium concentration from 3 x 10-3 M to 5 x 10-12 M. In contrast, whereas calcium levels in serum chelated with MgEGTA (0.01 M) are also quite low (1.7 x 10-9 M), magnesium levels are four times normal (4 x 10-3 M) (2) . It is reasonable to expect more nearly physiological function of the alternative pathway in serum with a more nearly normal concentration of magnesium, and many investigators have turned to MgEGTA in preference to EGTA.
Bryan observed that MgEGTA was clearly preferable to EGTA in studying serum bactericidal activity, since the lower levels of magnesium in EGTA-chelated serum rendered some bacteria artifactually sensitive to lysozyme (1). Forsgren and Quie (6) and Des Prez et al. (3) subsequently confirmed impairrnent of a variety of alternative pathway functions by EGTA.
This report provides further information regarding chelator inhibition of alternative pathway function. Depletion of C3-9 by Z was markedly slowed by EGTA (Fig. 1) ; and Z consumed less C in EGTA-chelated than in nonchelated serum, even when incubation was carried to 60 min (Fig. 2) . More importantly, C activation by Z in EGTA-chelated serum was significantly impaired compared to activation in MgEGTAchelated serum. Snyderman and Pike (14) showed that agents (such as Z) which activate both C pathways generally require an intact classical pathway for maximum efficiency; the slower Z activation in MgEGTA-chelated serum compared to nonchelated serum (Fig. 1 Fig. 2 support the notion that Mg-EGTA activates the alternative pathway. At 0.2 and 0.4 mg of Z per ml, more C3-9 was consumed in MgEGTA-chelated serum than in nonchelated serum; differences were significant at the 0.025 level but not at the 0.01 level. Table  2 provides stronger support. E-PNH, which have been shown to be lysed via the alternative pathway (7), underwent lysis in serum to which MgEGTA had been added. Bryant and Jenkins made this same observation some years ago (2) .
No evidence could be found to support the contention that MgEGTA either spontaneously activates C2 or facilitates C2 activation by Z. Hemolytic C2 levels in serum chelated with MgEGTA, with or without added Z, did not differ from C2 levels in nonchelated serum (Table 1) .
From the present study, one can make several conclusions regarding the use of chelators to dissect the pathways of complement activation. First, MgEGTA chelation provides a more nearly physiological milieu for alternative pathway function than does EGTA chelation, while still effectively inhibiting the classical pathway. MgEGTA has one important disadvantage, i.e., its tendency to activate spontaneously the alternative pathway. This effect may, for some purposes, be adequately counteracted by attention to a chelated serum control. In other circumstances it may be critical to avoid any spontaneous activation, in which case EGTA remains a useful chelator. Provided excess challenge material (e.g., 2 mg of Z) and prolonged incubation time (e.g., 60 min) are provided, complement activation in EGTA-chelated serum specifically reflects alternative pathway function.
